![\"\"](\"https:\/\/www.wockhardt.com\/wp-content\/uploads\/2019\/08\/Chairman-DONE.jpg\")
\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\tCHAIRMAN'S PROFILE<\/h1>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\tBeing different and making a difference. That sums up the vision, philosophy, conviction and driving force behind Dr. Habil F Khorakiwala who revels in venturing down the road less travelled.<\/p>
He founded Wockhardt in 1967. Today, the Wockhardt Group is India\u2019s leading research-based, global healthcare enterprise with relevance in the fields of Pharmaceuticals, Biotechnology, Active Pharmaceutical Ingredients (APIs), and Super Speciality Hospitals.<\/p>
From daring to be the first pharmaceutical company to establish manufacturing facilities in Chhatrapati Sambhajinagar against familial advice to the contrary, to focusing on new drug development in the antibiotics space over two decades ago; from venturing early into biotechnology to acquiring pharmaceutical companies across Europe and USA; it is the unique vision, strong passion and deep conviction of Dr. Khorakiwala that has steered Wockhardt to emerge as a research-based, global pharmaceutical and biotechnology company with interests across the healthcare value chain.<\/p>
Wockhardt\u2019s New Drug Discovery programme has focussed on unmet need of Anti-bacterial drugs that are effective against the menace of untreatable superbugs. Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified Infectious Disease Product) for 6 of our Anti-bacterial discovery programmes \u2013 3 of them are Gram Negative and 3 Gram Positive effective against untreatable \u201cSuperbugs\u201d. It has a comprehensive Drug Discovery team and clinical organisation.<\/p>
Dr. Khorakiwala\u2019s strategic insights, focused approach and courage of his convictions, have resulted in Wockhardt notching up several firsts to its credit. These include the launch of PROXYVON, the first combination formulation in pain management; launch of the first recombinant product, BIOVAC-B; and the launch of India\u2019s 1st automatic insulin delivery device, WOSULIN PEN + Cartridges; among others.<\/p>
Dr. Khorakiwala\u2019s academic qualifications include a Bachelor\u2019s degree in Pharmacy from India, a Master\u2019s degree in Pharmaceutical Science from Purdue University, USA, and an Advanced Management Program at the Harvard Business School, Boston, USA. Honoured with the title of \u2018Distinguished Alumnus\u2019 for significant contribution to the profession of pharmacy by his alma mater, Dr. Khorakiwala became the first non-American in 125 years to be conferred with an Honorary Doctorate by Purdue University (Pharmacy School) in 2010.<\/p>
Over the years, Dr. Khorakiwala has been actively involved in the public space, holding leadership positions at various industry bodies and forums and has been recognised, lauded, awarded and honoured by numerous national and global institutions and organisations.<\/p>
A member of the World Economic Forum (Davos), he has helmed, as President, FICCI (Federation of Indian Chambers of Commerce & Industry) as well as IPA (Indian Pharmaceutical Alliance). He was also the Chairman of the Board of Governors at the Centre for Organisation Development. He was the Chancellor of Jamia Hamdard University, New Delhi, which is an outstanding institution of higher learning with distinct and focused academic programmes.<\/p>
In 2017, Dr. Khorakiwala authored \u2018Odyssey of Courage\u2019, a book chronicling his entrepreneurial journey, and in 2018, he established the Wockhardt School of Courage, a unique mentorship programme for young and budding entrepreneurs, which was based on tenets, principles and insights drawn from the book.<\/p>
Dr. Khorakiwala with his mantra of \u2018Vision to Execute\u2019, has successfully led Wockhardt to be a major Indian Pharmaceutical company that holds a strong presence in key global economies today. Amidst continuous business diversification, Corporate Social Responsibility has remained close to his heart for which he instituted Wockhardt Foundation committed to human welfare.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\n\t\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\n\t\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t<\/i>\n\t\t\t\t\t\t\t<\/i>\n\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\tIndustry Level Participation<\/a>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t- Past President of FICCI (Federation of Indian Chambers of Commerce & Industry)<\/li>
- Past President of the Indian Pharmaceutical Alliance (IPA), the organisation of research-based pharmaceutical companies in India<\/li><\/ul><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t<\/i>\n\t\t\t\t\t\t\t<\/i>\n\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\tGovernment of India Nominations<\/a>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t
- Member of the National Manufacturing Competitiveness Council set up by Dr. Manmohan Singh, Prime Minister of India<\/li>
- Nominated by Govt. of India to the National Managing Committee, Indian Red Cross Society<\/li>
- Nominated by the Prime Minister of India to the Advisory Board of CSIR [Council of Scientific and Industrial Research] in New Delhi<\/li>
- Member of BOT (Board of Trade) instituted by the Government of India under the Ministry of Commerce & Industry<\/li>
- Nominated by the Government of India as member of the Board of Directors of NIPER (National Institute of Pharmaceutical Education and Research)<\/li><\/ul><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t<\/i>\n\t\t\t\t\t\t\t<\/i>\n\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\tAwards & Accolades<\/a>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t
- Shiromani Vikas Award for \u2018Outstanding and Inspiring Contribution towards National Development\u2019 at the hands of Mother Teresa in 1992<\/li>
- Institute of Marketing & Management (IMM) \u2018Top CEO\u2019 in 2002<\/li>
- International Medical Integration Council \u2018Life Time Achievement\u2019 in 2003<\/li>
- Giants Award for \u2018Outstanding Contribution to Business and Industry\u2019 in 2003<\/li>
- Rotary Award for Vocational Excellence, 2003-04<\/li>
- Ernst & Young \u2018Entrepreneur of the Year\u2019 in the Healthcare and Life Sciences category in 2004<\/li>
- Named \u2018India\u2019s Greatest Brand Builders\u2019 in a book authored by Dr. R L Bhatia of Centre for Change Management in 2005<\/li>
- Indian Express Group of Newspapers \u2018Lifetime Achievement Award\u2019 at the Pharma Excellence Awards 2006<\/li>
- UK Trade & Investment \u2018Entrepreneur of the Year\u2019 at the India Business Awards 2008<\/li>
- \u2018Honorary Doctorate in Pharmacy\u2019 conferred by Purdue University in 2010<\/li>
- Frost & Sullivan \u2018Lifetime Achievement Award\u2019 at the India Healthcare Excellence Awards 2012<\/li>
- ‘Global Indian of the Year 2018-19’ award from AsiaOne Magazine & URS Media Consulting PL<\/li>
- Recognised as one of the 75 change makers in the healthcare industry in the last 75 years<\/li>
- \u2018AsiaOne Bharatiya Mahanatam Vikas Puraskar (BMVP)\u2019 2021-22<\/li>
- Dr. Habil Khorakiwala bestowed Lifetime Achievement award by Integrated Health and Wellbeing Council in 2024<\/li><\/ul><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t<\/i>\n\t\t\t\t\t\t\t<\/i>\n\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\tInternational Honour<\/a>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t
Being different and making a difference. That sums up the vision, philosophy, conviction and driving force behind Dr. Habil F Khorakiwala who revels in venturing down the road less travelled.<\/p>
He founded Wockhardt in 1967. Today, the Wockhardt Group is India\u2019s leading research-based, global healthcare enterprise with relevance in the fields of Pharmaceuticals, Biotechnology, Active Pharmaceutical Ingredients (APIs), and Super Speciality Hospitals.<\/p>
From daring to be the first pharmaceutical company to establish manufacturing facilities in Chhatrapati Sambhajinagar against familial advice to the contrary, to focusing on new drug development in the antibiotics space over two decades ago; from venturing early into biotechnology to acquiring pharmaceutical companies across Europe and USA; it is the unique vision, strong passion and deep conviction of Dr. Khorakiwala that has steered Wockhardt to emerge as a research-based, global pharmaceutical and biotechnology company with interests across the healthcare value chain.<\/p>
Wockhardt\u2019s New Drug Discovery programme has focussed on unmet need of Anti-bacterial drugs that are effective against the menace of untreatable superbugs. Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified Infectious Disease Product) for 6 of our Anti-bacterial discovery programmes \u2013 3 of them are Gram Negative and 3 Gram Positive effective against untreatable \u201cSuperbugs\u201d. It has a comprehensive Drug Discovery team and clinical organisation.<\/p>
Dr. Khorakiwala\u2019s strategic insights, focused approach and courage of his convictions, have resulted in Wockhardt notching up several firsts to its credit. These include the launch of PROXYVON, the first combination formulation in pain management; launch of the first recombinant product, BIOVAC-B; and the launch of India\u2019s 1st automatic insulin delivery device, WOSULIN PEN + Cartridges; among others.<\/p>
Dr. Khorakiwala\u2019s academic qualifications include a Bachelor\u2019s degree in Pharmacy from India, a Master\u2019s degree in Pharmaceutical Science from Purdue University, USA, and an Advanced Management Program at the Harvard Business School, Boston, USA. Honoured with the title of \u2018Distinguished Alumnus\u2019 for significant contribution to the profession of pharmacy by his alma mater, Dr. Khorakiwala became the first non-American in 125 years to be conferred with an Honorary Doctorate by Purdue University (Pharmacy School) in 2010.<\/p>
Over the years, Dr. Khorakiwala has been actively involved in the public space, holding leadership positions at various industry bodies and forums and has been recognised, lauded, awarded and honoured by numerous national and global institutions and organisations.<\/p>
A member of the World Economic Forum (Davos), he has helmed, as President, FICCI (Federation of Indian Chambers of Commerce & Industry) as well as IPA (Indian Pharmaceutical Alliance). He was also the Chairman of the Board of Governors at the Centre for Organisation Development. He was the Chancellor of Jamia Hamdard University, New Delhi, which is an outstanding institution of higher learning with distinct and focused academic programmes.<\/p>
In 2017, Dr. Khorakiwala authored \u2018Odyssey of Courage\u2019, a book chronicling his entrepreneurial journey, and in 2018, he established the Wockhardt School of Courage, a unique mentorship programme for young and budding entrepreneurs, which was based on tenets, principles and insights drawn from the book.<\/p>
Dr. Khorakiwala with his mantra of \u2018Vision to Execute\u2019, has successfully led Wockhardt to be a major Indian Pharmaceutical company that holds a strong presence in key global economies today. Amidst continuous business diversification, Corporate Social Responsibility has remained close to his heart for which he instituted Wockhardt Foundation committed to human welfare.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t